Navigation path

Policy areas
Who is in charge?
Competition and you
In this section:
What's new?
Cases >
ECN Pharma Report
Sector inquiry
Life cycles in pharma


The life cycle of pharmaceutical products

The focus of competition law scrutiny, whether in merger control or in antitrust investigations, will vary depending on the stage of a product’s life cycle.

The life cycle of any new medicine begins with a new chemical compound, which is usually discovered through basic research conducted by so-called “originator manufacturers” or independent research facilities (universities, specialised laboratories) that are often supported by public funding. Once the basic research is completed, the pharmaceutical product containing the chemical compound is tested to verify if it would be safe and effective.

Once studies have shown that a new medicine is safe and effective, the originator company applies for a marketing authorisation to the competent regulatory agency. This could be either the European Medicines Agency (EMA) or a national authority.

The development cycles for innovative drugs are usually risky and lengthy, and entail high development costs. Recent estimates suggest that the costs of bringing a medicine from the lab to the market are between EUR 0.5 billion and EUR 2.2 billion (converted from USD) - see the Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe, Final Report, May 2018 by Copenhagen Economics. Moreover, only a small minority of candidate molecules survive the development stage and finally make it to the market.

Pharmaceutical (originator) companies may enjoy an exclusivity on the market through patent protection for their products in order to recoup such research and development costs. Once the awarded patent has expired, producers of copy (so-called “generic”) products can enter the market. Such "generic entry” has typically the effect of bolstering competition and of driving prices for competing pharmaceuticals down.

Certain practices of pharmaceutical companies to protect their exclusivity may, under certain circumstances, lead to violations of EU competition law. These include, for example, patent clusters, patent thickets and patent settlements, which aim at prolonging market-exclusivity, and other anti-competitive strategies that result in higher prices. These types of behaviour entail not only the risk of price increases, but can also take away the incentive to innovate. More information

In the AstraZeneca case, the Commission investigated AstraZeneca's suspected abuse of the patent system and the system for authorisation of medicines, with the aim of delaying competition to a blockbuster drug from generic and parallel imported pharmaceuticals. The abuse of Astra Zeneca consisted in providing misleading information to a number of EEA patent offices in order to obtain supplementary protection certificates (SPCs) and misusing rules and procedures applied by national medicines agencies by selectively deregistering its market authorisations. AstraZeneca was fined EUR 60 million in 2005.